More than 60% of all rearrangements found in pediatric AML target only five different protein complexes: the core binding factor (CBF), the epigenetic regulator MLL, the nuclear receptor RARA, and the nuclear pore component NUP98 [1,2]. This evidence concerns the gene RARA and acute myeloid leukemia.